Severe bullous systemic lupus erythematosus successfully treated with low dose rituximab: a case report from sub-Saharan Africa

Abstract

Bullous systemic lupus erythematosus (BSLE) is a blistering skin condition occurring in lupus patients. Although cutaneous manifestations are common in lupus (59-85%), BSLE is rare, affecting <5% of lupus patients with very few reported cases among Africans. Dapsone is effective in mild to moderate cases, but off-label standard-dose rituximab (1,000 mg 2 weeks apart) has led to good outcomes in refractory cases. We report the case of a 39-yearold African lady with BSLE, who was successfully treated with low-dose rituximab (500 mg 2 weeks apart), healing her skin lesions at one year post-treatment. Low-dose rituximab may be as effective as standard dosing for the treatment of severe bullous SLE and is recommended in low resource settings.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2020-07-23
Info
Issue
Section
Case Reports
Keywords:
Bullous lupus, rituximab, Africans, case report
Statistics
  • Abstract views: 204

  • PDF: 119
How to Cite
Akpabio, A., & Otike-Odibi, B. (2020). Severe bullous systemic lupus erythematosus successfully treated with low dose rituximab: a case report from sub-Saharan Africa. Reumatismo, 72(2), 115-119. https://doi.org/10.4081/reumatismo.2020.1274